OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic OsteosarcomaOctober 10, 2025 6:00 AM EDT | Source: OS Therapies75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year overall survivalNew York, New ...

OS Therapies to Participate in Fall 2025 Conferences and EventsOctober 07, 2025 11:50 AM EDT | Source: OS TherapiesDaytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated in OST-HER2 clinical trialsNew York, New York--(Newsfile Corp. - October 7, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer ...

Core Viewpoint - Liminatus Pharma, Inc. plans to strategically expand into the cryptocurrency sector by establishing a subsidiary focused on accumulating BNB Coin, with a target investment of up to $500 million for long-term value [1][2][4]. Company Strategy - The new subsidiary, "American BNB Strategy," will lead the digital asset investment initiatives, aiming to raise and deploy capital in phases [2][4]. - The investment strategy is characterized as a long-term value-driven approach rather than a short-term speculative initiative [4][5]. Rationale for Investment - BNB Coin was chosen due to its robust technology, global user base, and value-generating features such as Launchpool participation and staking models [5]. - The company believes that entering the digital asset space is essential for long-term growth and enhancing shareholder value while remaining committed to its core business of cancer therapeutics [3][6]. Operational Framework - Liminatus plans to utilize custody infrastructure from Ceffu, an entity within the BNB ecosystem, to ensure security and operational integrity in its digital asset investments [6]. - The company is currently engaged in a capital raise process with placement agent Digital Offering, pending regulatory clearance and market conditions [8]. Industry Impact - This initiative marks a rare move for a traditional biopharmaceutical company, potentially setting a precedent for how other Nasdaq-listed companies engage with the digital asset economy [7].